2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

801. Gene Therapies: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Omics Technologies, Bioinformatics, Cell Expansion, Computational Biology, Emerging Technologies, Gene Editing, Treatment Considerations, Drug Development, Biological Therapies, Transplantation, Chimeric Antigen Receptor, Gene Therapy, Artificial Intelligence (AI), Machine Learning, Biological Processes, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Molecular Biology, Diseases, Bleeding and Clotting, Hemophilia, Genetic Disorders, Hemoglobinopathies, Sickle Cell Disease, Thalassemia, Immunology, Autoimmune Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Research, Translational Research, Clinical Research, Clinical Trials, Study Population, Human, Pediatric, Animal Model
PAPER

2551 Long-term durability, efficacy, and safety of SPK-8011 gene therapy for hemophilia A

Lindsey George, MD, Stacy Croteau, MD2, M. Elaine Eyster, MD3, Huyen Tran, MBBS4, Jill Moormeier5, Gili Kenet6, Marianne Uguen7, Athina Voulgari, PhD8, Sasha Sreckovic9, Sarah Consonni10
1 Children’s Hospital of Philadelphia and University of Pennsylvania, Philadelphia, Pennsylvania, United States
2 Boston Children’s Hospital, Boston, Massachusetts, United States
3 Milton S. Hershey Medical Center and Penn State College of Medicine, Hershey, Pennsylvania, United States
4 The Alfred Hospital, Melbourne, Victoria, Australia
5 University of Missouri-Kansas City School of Medicine, Kansas City, Missouri, United States
6 National Hemophilia Center and Thrombosis Institute, Sheba Medical Center, Tel Aviv, Israel and Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel
7 F. Hoffmann-La Roche Ltd, Basel, Switzerland
8 Roche Products Ltd, Welwyn Garden City, United Kingdom
9 Genentech, Inc., South San Francisco, California, United States
10 Roche Products Ltd, Welwyn Garden City, United Kingdom

Background: The goal of adeno-associated virus (AAV) gene therapy for hemophilia A (HA) is to provide a cure, which safely provides predictable and durable factor (F)VIII expression that normalizes hemostasis, to enable freedom from prophylaxis and to achieve a hemophilia-free mind. SPK-8011 (dirloctocogene samoparvovec) was an investigational AAV gene therapy for HA, which utilized doses lower than other AAV gene therapies aiming to minimize toxicity and provide durable FVIII expression. Here, we detail the long-term durability, efficacy, and safety of SPK-8011.

Methods: Adult males with severe or moderately severe HA (≤2% FVIII activity) were enrolled in this Phase I/II trial and subsequent long-term follow-up (LTFU) study (NCT03003533/NCT03432520). Long-term FVIII activity levels (i.e. durability) and efficacy were monitored, as well as safety data.

Results: As of November 24, 2025, 25 participants had been enrolled. Participants were sequentially enrolled into 3 escalating dose cohorts: 5×1011 vg/kg (n=2), 1×1012 vg/kg (n=3), 2×1012 vg/kg (n=9). A fourth cohort of 1.5×1012 vg/kg was opened (n=11) after 2 participants from the 2×1012 vg/kg cohort lost FVIII activity due to a presumed capsid immune response, inadequately controlled by immunosuppression, while 2 other participants from the same cohort had supraphysiologic FVIII levels of 208.6% and 194.2%. At baseline, 20 participants (80%) were on prior FVIII prophylaxis and 5 (20%) were treated on demand. Of the 25 participants in LTFU, 18 remain on study, 2 completed the initial 4-year study but declined extension, and 5 discontinued during LTFU, due to loss to follow-up (n=3), withdrawal (n=1), or site closure (n=1).

All 25 participants expressed transgene-encoded FVIII. Following an initial transient high-expression phase, FVIII activity plateaued and was sustained past 1 year in 23 participants (92%). Median FVIII activity ranged from 10.1% (min–max: 1.9–28.3%; n=22) after 1 year post vector to 11.4% (min–max: 5.4–17.3%; n=4) in Year 8, measured by one-stage assay.

Analysis of annualized bleeding rate (ABR) showed meaningful control of bleed events across all cohorts. The mean ABR for total bleeds post vector was 1.8 (standard deviation [SD]: 2.7) compared with 15.2 (SD: 28.4) in the 52 weeks prior to SPK-8011 infusion. Thirteen participants had an ABR ≤1, 5 had an ABR >1–2, and the remaining 7 had an ABR >2 post vector.

Seven participants (28%) returned to prophylaxis. Three were in the 2×1012vg/kg cohort: 2 within the first year (at 4 months and 1 year) post vector due to an early immune-mediated loss of FVIII activity to <1% and 2%, respectively, and 1 after 5 years post vector due to dissatisfaction with breakthrough bleeds (FVIII: 4.3%). The remaining 4 participants were in the 1.5×1012 vg/kg cohort, all due to FVIII levels <5% with associated joint bleeds or pain: 2 returned to prophylaxis at 1.8 and 1.9 years post vector (FVIII: 1.8% and 3.7%, respectively), 1 at 3.1 years (FVIII: 4.5%), and 1 at 5.1 years (FVIII: 1.1%). FVIII activity levels remained stable long-term in the majority of participants who returned to prophylaxis (excluding early immune-mediated loss), albeit at levels clinically insufficient for complete hemostatic protection.

To date, SPK-8011 has demonstrated a well-tolerated safety profile. Transaminase elevations were generally mild/moderate, clinically asymptomatic, and transient. Post-vector liver ultrasound results were unremarkable for most participants, with few incidental findings deemed unrelated to treatment and with no tumorigenic risk.

Conclusions: Low-dose AAV gene transfer with SPK-8011 achieved stable multi-year FVIII activity for most participants, with meaningful reductions in ABR. The 1.5×1012 vg/kg cohort demonstrated the most favorable profile, maintaining sustained FVIII expression without early loss of expression or supraphysiological levels. These data validate the long-term efficacy and durability of low-dose SPK-8011 for HA, supporting advancement of this platform into an ongoing Phase IIb trial (NCT07226206) with the enhanced-function SPK-8011QQ transgene variant.

Lindsey George, MD: Form.Bio - Current holder of stock options in a privately-held company; F. Hoffmann-La Roche Ltd - Research Funding; F. Hoffmann-La Roche Ltd - Patents & Royalties; F. Hoffmann-La Roche Ltd - Consultancy (Includes expert testimony); CSL Behring, Astellas Therapeutics, Voyager Therapeutics - Consultancy (Includes expert testimony)